期刊文献+

米非司酮阴道环的含量及有关物质测定方法的研究 被引量:5

Determination of mifepristone and its related substances in drug loaded vaginal ring
原文传递
导出
摘要 目的:建立米非司酮(RU486)阴道环的含量及其有关物质的高效液相色谱测定方法。方法:色谱柱为Diamonsil C18柱(250 mm×4.6 mm,5μm),流动相为甲醇-水(0.05%三乙胺)(75∶25),流速为1.0mL.min-1,检测波长为304 nm。结果:米非司酮与相关杂质及降解产物均分离良好,空白辅料对测定无干扰。米非司酮在0.5~12.0μg.mL-1范围内具有良好的线性关系(r=0.999 9),最低检测限为10 ng.mL-1,平均回收率为100.5%。结论:本方法用于米非司酮阴道环的质量评价,操作简便,定量准确,专属性强,灵敏度高,重复性好。 Objective: To develop an HPLC method for determining the content of mifepristone and related substances in vaginal ring. Methods: The separation and determination were accomplished on a Diamonsil C18 (250 mm × 4.6 mm, 5μm) column with UV detection at 304 nm. The mobile phase consisted of methanol and water (75:25 ) containing 0.05% triethylamine at a flow rate of 1.0 mL. min-1 Results : The good separation was obtained for mifepristone and its related substances, and their determination was not interfered by the excipients.The calibration curve of mifepristone had acceptable linearity in the range of 0.5 - 12.0 μg· mL^-1 ( r = 0. 999 9 ). The lowest limit of determination was 10 ng·mL^-1 The average recovery was 100.5%. Conclusion: The procedure of pretreatment was simple, and this method is accurate and reliable with a good reproducibility. It can be used in the quality evaluation of mifepristone vaginal ring.
出处 《中国新药杂志》 CAS CSCD 北大核心 2013年第5期598-601,共4页 Chinese Journal of New Drugs
基金 国家十二五科技支撑计划(2012BAI31B00)
关键词 米非司酮 阴道环 含量测定 有关物质 高效液相色谱法 mifeprlstone vaginal ring determination related substances HPLC
  • 相关文献

参考文献15

  • 1SPITZ IM. Progesterone antagonists and progesterone receptor modulators [ J ]. Steroids,2003,12 ( 10 ) : 1693 - 1707. 被引量:1
  • 2QUEREUX C,RAIMOND E,GRAESSLIN O. Oral contraceptives and non-oral contraceptives:realities [ J ] . J Fynecol Obstet Biol Reprod (Paris) ,2009,5 ( 38 ) :69 - 83. 被引量:1
  • 3NOVA'K A,DE LA LOGE C,ABETZ L,et al. The combined contraceptive vaginal ring, NuvaRing:an international study of us- er acceptability [ J ]. Contraception, 2003,67 ( 3 ) : 187 - 194. 被引量:1
  • 4NATH A,SITRUK-WARE R. Progesterone vaginal ring for con- traceptive use during lactation[ J]. Contraception ,2010,82 ( 5 ) : 428 - 434. 被引量:1
  • 5BARREIROS FA, FALBO GCA, BARBOSA R, et al. Extended regiments of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism [ J ]. Contraception, 2011,84 ( 2 ) : 155 - 159. 被引量:1
  • 6SALIHE SI. Intravaginal rings with insertable drug-containing core: 中国,97190991.1[P]. 1998 -03 -30. 被引量:1
  • 7周菊贤,刘晓瑷.新型非口服激素避孕方式的研究进展[J].国际生殖健康/计划生育杂志,2009,28(4):246-248. 被引量:7
  • 8FINE PM,TRYQQESTAD J, MEYERS NJ,et al. Safety and ac- ceptability with the use of a contraceptive vaginal ring after surgi- cal or medical abortion [ J ]. Contraception,2007,75 (5) :367 - 371. 被引量:1
  • 9MULDERS TM,DIEBEN TO. Use of the novel combined contra- ceptive vaginal ring NuvaRing for ovulation inhibition [ J]. Fertil Steril,2001,75 ( 5 ) : 865 - 870. 被引量:1
  • 10VARTIAINEN J,WAHLSTROM T,NILSSON CG. Effects and acceptability of a new 17 beta-oestradiol-releasing vaginal ring in the treatment of postmenopausal complaints [ J ]. Maturitas, 1993,17(2) :129 - 137. 被引量:1

二级参考文献32

  • 1侯冬枝,谢长生,朱长虹.米非司酮固体脂质纳米粒的性状研究[J].中国医药工业杂志,2004,35(10):602-605. 被引量:6
  • 2杨鹏晖,袁和亮,史晖,张晓东,李光平.米非司酮阴道贴膜的研究[J].中国医药工业杂志,1994,25(5):204-207. 被引量:5
  • 3O'Connell K, Burkman RT. The transdermal contraceptive patch: an updated review of the literature [J]. Clin Obstet Gynecol, 2007, 50 (4): 918-926. 被引量:1
  • 4Burkman RT. Transdennal hormonal contraception: benefits and risks[J]. Am J Obstet Gynecol, 2007, 197(2): 134. e1-6. 被引量:1
  • 5Piyasirisilp R, Taneepanichskul S. A clinical study of tnmsdermal contraceptive patch in Thai adolescence women[J]. J Mad Assoc Thai, 2008, 91(2): 137-141. 被引量:1
  • 6Zurawin ILK, Ayensu-Coker L. Innovations in contraception: a review[J]. Clin Obstet Gynecol, 2007, 50(2): 425-439. 被引量:1
  • 7Swica Y. The transdermal patch and the vaginal ring: two novel methods of combined hormonal contraception [J]. Obstet Gynecol Clin North Am, 2007, 34(1): 31-42. 被引量:1
  • 8Jick SS, Kaye JA, Russmann S, et al. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel[J]. Contraception, 2006, 73(6): 566-570. 被引量:1
  • 9Cole JA, Norman H, Doherty M, et al. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users[J]. Obstet Gynecol, 2007, 109(2): 339-346. 被引量:1
  • 10Tolaymat LL, Kaunitz AM. Long-acting contraceptives in adolescents[J]. Curt Opin Obstet Gynecol, 2007, 19(5): 453-460. 被引量:1

共引文献11

同被引文献61

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部